ArticleCureus2025
A Real-World Evaluation of Definisse Filler for Facial Rejuvenation in Indian Patients: The REDEFINE REJUVENATION Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective India's burgeoning aesthetic medicine sector has witnessed exponential growth, driven by increasing disposable incomes, social media influence, and a growing acceptance of cosmetic procedures. The approval of the first hyaluronic acid (HA) filler in 2003 initiated a wave of innovation; advancements in cross-linking and formulation now allow for tailored treatments across diverse patient needs and anatomical regions. The most recent addition to HA fillers, Definisse filler (RELIFE S.r.l., Florence, Italy) has gained attention specifically due to its proprietary manufacturing process, known as the eXcellent Three-Dimensional Reticulation (XTR) technology. However, it lacks robust real-world data in the Indian context. Hence, this study aimed to evaluate the safety and efficacy of Definisse fillers in a real-world setting among Indian patients. Methodology This was a multicenter, retrospective observational study that evaluated Indian adult patients who received facial rejuvenation treatments using the Definisse filler range (Touch, Restore, and Core). The study analyzed real-world clinical data to assess treatment outcomes, including efficacy and safety profiles in a diverse patient population. Results The study included 304 patients, with a mean follow-up duration of 3.9 months and an average age of 41.0 years. An average of 4.4 ml of Definisse filler was administered per patient. Both the Physician and Subject Global Aesthetic Improvement Scales (PGAIS and SGAIS) demonstrated immediate post-treatment improvement, with mean scores of 3.9 and 3.87, respectively. Further enhancement was observed during follow-up visits, with mean scores increasing to 4.37 and 4.33, respectively (p < 0.001 for both). Overall, about 90% of patients exhibited either 'much improvement' or 'very much improvement' on PGAIS at the follow-up visit. Most procedure-related adverse events were mild and resolved spontaneously within a few days without the need for active intervention. Conclusions The findings of this multicenter, real-world study indicate that Definisse fillers are clinically effective and exhibit a positive safety profile for facial rejuvenation in Indian patients. While these results show consistent clinical improvement, it must be noted that the study was designed as observational and retrospective and had a short mean follow-up. These findings provide valuable guidance for initial clinical practice, and further prospective studies are warranted to confirm long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.